Therapeutically active compounds and their methods of use
Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
1. A compound which is
or a pharmaceutically acceptable salt or hydrate thereof.
2. A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable carrier.
3. A method of treating a cancer characterized by the presence of an IDH2 mutation, wherein the IDH2 mutation results in a new ability of the enzyme to catalyze the NADPH dependent reduction of a ketoglutarate to R(−) 2 hydroxyglutarate in a patient, comprising the step of administering to the patient in need thereof a compound of claim 1 .
4. The method of claim 3 , wherein the IDH2 mutation is an IDH2 R140Q or R172K mutation.
5. The method of claim 3 , wherein the IDH2 mutation is an IDH2 R140Q mutation.
6. The method of claim 3 , wherein the cancer is selected from the group consisting of glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non small cell lung cancer, chondrosarcoma, cholangiocarcinomas and angioimmunoblastic non-Hodgkin's lymphoma.
7. The method of claim 3 , wherein the cancer is acute myelogenous leukemia.
8. The method of claim 3 , further comprising administering to the patient in need thereof a second therapeutic agent useful in the treatment of cancer.